- Home
- XBP vs SPRO Comparison
XBP vs SPRO Comparison
Compare XBP & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBP
- SPRO
- Stock Information
- Founded
- XBP N/A
- SPRO 2013
- Country
- XBP United Kingdom
- SPRO United States
- Employees
- XBP N/A
- SPRO N/A
- Industry
- XBP Business Services
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- XBP Consumer Discretionary
- SPRO Health Care
- Exchange
- XBP Nasdaq
- SPRO Nasdaq
- Market Cap
- XBP 32.2M
- SPRO 33.0M
- IPO Year
- XBP N/A
- SPRO 2017
- Fundamental
- Price
- XBP $1.03
- SPRO $2.50
- Analyst Decision
- XBP
- SPRO Buy
- Analyst Count
- XBP 0
- SPRO 4
- Target Price
- XBP N/A
- SPRO $5.00
- AVG Volume (30 Days)
- XBP 35.1K
- SPRO 10.8M
- Earning Date
- XBP 05-15-2025
- SPRO 05-13-2025
- Dividend Yield
- XBP N/A
- SPRO N/A
- EPS Growth
- XBP N/A
- SPRO N/A
- EPS
- XBP N/A
- SPRO N/A
- Revenue
- XBP $142,332,000.00
- SPRO $44,584,000.00
- Revenue This Year
- XBP N/A
- SPRO N/A
- Revenue Next Year
- XBP N/A
- SPRO N/A
- P/E Ratio
- XBP N/A
- SPRO N/A
- Revenue Growth
- XBP N/A
- SPRO N/A
- 52 Week Low
- XBP $0.79
- SPRO $0.51
- 52 Week High
- XBP $2.27
- SPRO $2.80
- Technical
- Relative Strength Index (RSI)
- XBP 40.40
- SPRO 86.18
- Support Level
- XBP $1.00
- SPRO $0.66
- Resistance Level
- XBP $1.13
- SPRO $2.48
- Average True Range (ATR)
- XBP 0.08
- SPRO 0.13
- MACD
- XBP -0.01
- SPRO 0.20
- Stochastic Oscillator
- XBP 13.05
- SPRO 86.36
About XBP XBP Europe Holdings Inc.
XBP Europe Holdings Inc is a pan-European integrator of bills, payments, and related solutions and services seeking to enable digital transformation. It provides business process management solutions with proprietary software suites and deep domain expertise, serving as a technology and operations partner for its clients' strategic journeys and streamlining their complex, disconnected payment processes. It has two segments Bills and Payments focusing on optimizing how bills and payments are processed by businesses of all sizes and industries and Technology, focuses on sales of recurring and perpetual software licenses and related maintenance, hardware solutions, and related maintenance and professional services. It generates the majority of its revenue from the Bills and Payments segment.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.